Plasma levels of type 1 plasminogen activator inhibitor (PAI-1), a risk factor for cardiovascular disease, are elevated in obese subjects, especially those with omental fat accumulation. We investigated the hormonal control of PAI-1 gene expression and secretion in cultured human adipose tissue. We more particularly focused on the effects of glucocorticoids, insulin, cAMP, and catecholamines in explants from the omental region. The addition of dexamethasone to the culture medium increased PAI-1 secretion in a time-dependent manner for up to 24 h. The stimulation by the glucocorticoid was preceded by a 2-fold rise in PAI-1 messenger ribonucleic acid levels between 4 -8 h of culture. The effectiveness of the glucocorticoid was concentration dependent, with a halfmaximal effect within a physiological range. This stimulation was also observed in sc fat, but dexamethasone-stimulated as well as basal PAI-1 secretion rates were always higher in omental fat. Unlike dexamethasone, 24-h insulin did not modify PAI-1 secretion while accelerating glucose consumption. In contrast, 24-h cAMP inhibited PAI-1 gene expression and protein production under basal conditions and in the presence of dexamethasone. This inhibition was already detectable after 1 h and was maximal after 4 h at the level of gene expression. It occurred in both omental and sc adipose tissues. Importantly, epinephrine dose dependently inhibited PAI-1 parameters, an effect that was reproduced by isoproterenol. Dexamethasone-and cAMP-induced changes in PAI-1 messenger ribonucleic acid abundance were similar in explants and isolated fat cells. In isolated stromal-vascular cells, only dexamethasone was effective. In conclusion, we provide evidence for a reciprocal regulation of PAI-1 by dexamethasone (positive effector) and cAMP/catecholamines (negative effectors) in cultured human adipose tissue. The stimulation by glucocorticoids could contribute to enhanced production of PAI-1 by adipose tissue and high plasma levels of PAI-1 associated with central obesity and thereby be a link between this disorder and cardiovascular disease. Impaired inhibition by catecholamines could also contribute, as in vivo adipose tissue responses to these hormones are usually blunted in obese individuals. (J Clin Endocrinol Metab 84: 4097-4105, 1999) 
basal conditions and in the presence of dexamethasone. This inhibition was already detectable after 1 h and was maximal after 4 h at the level of gene expression. It occurred in both omental and sc adipose tissues. Importantly, epinephrine dose dependently inhibited PAI-1 parameters, an effect that was reproduced by isoproterenol. Dexamethasone-and cAMP-induced changes in PAI-1 messenger ribonucleic acid abundance were similar in explants and isolated fat cells. In isolated stromal-vascular cells, only dexamethasone was effective. In conclusion, we provide evidence for a reciprocal regulation of PAI-1 by dexamethasone (positive effector) and cAMP/catecholamines (negative effectors) in cultured human adipose tissue. The stimulation by glucocorticoids could contribute to enhanced production of PAI-1 by adipose tissue and high plasma levels of PAI-1 associated with central obesity and thereby be a link between this disorder and cardiovascular disease. Impaired inhibition by catecholamines could also contribute, as in vivo adipose tissue responses to these hormones are usually blunted in obese individuals. (J Clin Endocrinol Metab 84: [4097] [4098] [4099] [4100] [4101] [4102] [4103] [4104] [4105] 1999) O BESITY belongs to a cluster of metabolic abnormalities, including non-insulin-dependent diabetes, dyslipidemia, hypertension, and cardiovascular diseases, all of which are characteristics of the insulin resistance syndrome (1) . The predominant (central-omental vs. peripheral) site of body fat distribution rather than the level of obesity per se appears to be a stronger factor of this adverse metabolic profile (2) .
Type 1 plasminogen activator inhibitor (PAI-1) is a main regulator of the endogenous fibrinolytic system. It decreases fibrinolysis and promotes the progression of thrombosis (3, 4) . Plasma PAI-1 levels are related to overall fatness [body mass index (BMI)] and omental fat in particular and are elevated in obese subjects (3, (5) (6) (7) . As PAI-1 is a main risk factor for cardiovascular disease, it may be a pathogenetic link between atherothrombosis and obesity (3, 8) . However, the cellular and molecular basis of this connection is still elusive.
Increased fatness itself may contribute to high plasma PAI-1 activity. Indeed, it has recently been discovered that adipocytes have a secretory function (9) and that, besides leptin and other products, these cells can synthesize PAI-1 in rodents and in man (4, 7, 10, 11) . Unraveling the mechanisms involved in the regulation of PAI-1 production by adipose tissue is thus essential for our understanding of cardiovascular morbidity associated with obesity. Several endocrine abnormalities are associated with obesity. These include, in particular, hyperinsulinemia, enhanced glucocorticoid turnover (12) and altered sympathetic tone (13, 14) . Despite this, the direct role of hormones on PAI-1 production has been studied only in murine adipose cell lines (15) and more recently in human sc fat (16) , but never been addressed in human omental fat.
In the present study we therefore investigated the hormonal control of PAI-1 gene expression and production in cultured explants of human adipose tissue. We particularly focused on the effects of glucocorticoids, insulin, and cAMP (as second messenger of catecholamines) in adipose explants from the omental region.
Subjects and Methods Subjects
Adipose tissue was obtained from patients undergoing abdominal surgery after an overnight fast. We first compared two age-matched subgroups of seven lean (three men and four women; age, 53.7 Ϯ 3.7 yr; BMI, 23.9 Ϯ 1.0 kg/m 2 ) and eight obese (two men and six women; age, 45.0 Ϯ 4.0 yr; BMI, 40.7 Ϯ 1.6 kg/m 2 ) subjects for 24-h PAI-1 production (obesity being defined as a BMI of 30 kg/m 2 or more). There was no difference in PAI-1 production (micrograms per g adipose tissue) between the two subgroups (Table 1) . In other experiments, we did not attempt to discriminate the results in lean from those in obese subjects, and PAI-1 data from patients with different BMI were pooled. A total of 59 patients (26 men and 33 women; age, 51.2 Ϯ 2.0 yr; BMI, 29.7 Ϯ 1.0 kg/m 2 ) were studied. Gender did not influence the results, in agreement with previous work (11) . Thus, at 24 h, basal PAI-1 messenger ribonucleic acid (mRNA) levels [optical density (OD)] were 2.8 Ϯ 0.5 in men (n ϭ 10) and 2.9 Ϯ 0.7 in women (n ϭ 18), and PAI-1 secretion (micrograms per g) averaged 4.4 Ϯ 1.2 in men (n ϭ 8) and 3.8 Ϯ 1.0 in women (n ϭ 13; P Ͼ 0.05). All cases were elective procedures to correct benign conditions (gastroesophageal reflux, hernia repair, colonic diverticulosis, and overweight status treated by vertical banded gastroplasty) or malignant disease (carcinoma of colon). Cancer cases had no evidence of disseminated disease, and the operation was curative. Localized colorectal cancer did not modify PAI-1 data in adipose tissue (not shown). No patients had a history of diabetes, and none had undergone any significant weight change. Patients receiving endocrine therapy and/or taking medications known to influence adipose tissue mass or metabolism were excluded. The study had the approval of the local ethical committee.
For each culture, adipose tissue from only one subject was used. Due to the amount of tissue available, it was not possible to generate all data from all patients.
Adipose tissue or cell culture
One to 60 g omental and sc biopsies were placed in Krebs buffer, pH 7.4, containing 2% (wt/vol) BSA [Krebs-albumin buffer (KRAB)] and transported to the laboratory within 5-10 min after sampling. All visible vessels, coagulation particles, and conjunctive tissue were removed. Fat tissue was cut with scissors into small pieces (ϳ4 mm 3 ), then rinsed in phosphate-buffered saline and incubated in 100-mm petri dishes containing 9 mL MEM with Earle's salts supplemented with 10% FCS, 100 IU/mL penicillin, 100 g/mL streptomycin, and 0.25 g/mL amphotericin B (Gibco, Grand Island, NY). In some experiments, FCS was omitted and replaced by 1% BSA. Approximately 600-1000 mg adipose tissue were cultured per dish; all conditions were carried out in duplicate, then material was pooled. The dishes were cultured for up to 48 h at 37 C in an air-CO 2 (19:1) atmosphere. The basal concentration of glucose in fresh medium was 5 mmol/L. The basal concentrations of cortisol and insulin were extremely low (ϳ0.5 nmol/L and 3 pmol/L, respectively). Different hormones or pharmacological agents were used in various combinations in accordance with the experimental protocols. When isoproterenol or epinephrine was tested, ascorbic acid (100 mol/L) was added to prevent catecholamine degradation, and in this case MEM medium plus ascorbic acid served as the control condition. Cell viability, as assessed by low release of lactate dehydrogenase and triglycerides into the medium under basal conditions (17), did not change over the course of culture (not shown). At the end of the experiment, the adipose material was rinsed in phosphate-buffered saline, collected, immediately frozen in liquid nitrogen, and stored at Ϫ70 C until subsequent RNA extraction. Aliquots of medium were also saved and stored at Ϫ20 C for measurement of PAI-1 and glucose concentrations.
In some experiments, a sample of adipose tissue was simultaneously processed into isolated adipocytes (and stromal-vascular cells) by collagenase treatment according to the method of Rodbell (18) . Briefly, adipose tissue was finely minced and incubated for 1 h in a shaking water bath at 37 C in KRAB with collagenase A (3.3 mg/mL; Boehringer Mannheim, Mannheim, Germany). Digested tissue was filtered through a metallic mesh and centrifuged at 400 ϫ g for 1 min. The floating adipocyte layer was separated from the infranatant medium and washed three times in KRAB. In experiments in which large amounts of tissue were available, the infranatant was also saved and centrifuged again at 400 ϫ g for 3 min, then the pelleted stromal-vascular fraction was washed once and resuspended in KRAB (1 mL/6 g tissue). In methodological studies, the ob gene, which is specifically expressed in adipocytes (19) , was highly expressed in the adipocyte fraction, but was not detectable in the stromal-vascular fraction (not shown). For each experimental condition, the adipocytes were obtained from digestion of 1.2-6 g tissue, and the stromal-vascular fraction was obtained from 6 g tissue. Isolated adipocytes and stromal vascular cells were then cultured as described for tissue explants.
RNA extraction and Northern blot analysis
Total RNA was prepared with an acid guanidinium thiocyanatephenol-chloroform mixture as previously described (19) . The concentration of RNA was determined by absorbance at 260 nm. For Northern blot analysis, 10 g (3.5-7.5 g for comparisons among explants, isolated adipocytes, and stromal-vascular cells) total RNA were denatured in a solution containing 2.2 mmol/L formaldehyde and 50% (vol/vol) formamide by heating at 95 C for 2 min. RNA was then size-fractionated by 1% (wt/vol) agarose gel electrophoresis, transferred to a Hybond-N membrane (Amersham Pharmacia Biotech, Aylesbury, UK), and crosslinked by UV irradiation. The integrity and relative amounts of RNA were assessed by methylene blue staining of the blots.
The complementary DNA probes for the human PAI-1 and peroxisome proliferator-activated receptor-␥ (PPAR␥) were prepared as follows. Products of 604 and 457 bp were, respectively, obtained after RT-PCR on total RNA from human adipose tissue (PAI-1: sense primer, 5Ј-TTTGGTGAAGGGTCTGCTGTG-3Ј; antisense primer, 5Ј-TGCTGC-CGTCTGATTTGTGGAA-3Ј; PPAR␥: sense primer, 5Ј-ACCACTCC CACTCCTTTGAT-3Ј; antisense primer, 5Ј-GCATTATGAGACATC-CCCAC-3Ј). The identity of the appropriate size products was confirmed by mapping with restriction endonucleases. Human glyceraldehyde-3-phosphate dehydrogenase (GAPDH) complementary DNA was also amplified by PCR using commercially available primers (CLONTECH Laboratories, Inc., Palo Alto, CA). Hybridizations with the different radiolabeled probes were performed as previously reported (19) . The filters were then exposed to Kodak X-Omat AR films (Eastman Kodak Co., Rochester, NY) for 3-48 h at Ϫ70 C with intensifying screens. The same filters were hybridized successively with the different probes. The ODs of the mRNA bands on the blots and of ribosomal 18S RNA on membrane were quantified by scanning densitometry (Sharp Scanner JX 325 combined with Image Master Software, Pharmacia Biotech, Uppsala, Sweden). Levels of specific mRNAs were expressed relative to those of ribosomal 18S RNA. Internal standards (pooled RNA from two or three patients) were always loaded on each gel to allow direct comparisons between different blots.
PAI-1 antigen production
Levels of PAI-1 antigen in the culture medium were measured using a specific enzyme-linked immunosorbent assay as previously described (20) . The secretion rate was always expressed as micrograms of PAI-1 released per g wet tissue over the indicated time period. When lean and Omental adipose tissue from age-matched lean and obese subjects was cultured for 24 h in MEM without (basal) or with 50 nmol/L dexamethasone (Dexa 50). PAI-1 released in medium was expressed as micrograms per g tissue (or per g DNA)/24 h. Values are the mean Ϯ SE for five to seven lean and seven to eight obese subjects. There were no significant differences for lean vs. obese subjects.
a P Ͻ 0.05 or less for the effect of dexamethasone.
obese subjects were compared, the secretion rate was also expressed as micrograms of PAI-1 released per g tissue DNA over the indicated period.
Analytical procedures
Glucose concentrations were measured in medium, before and after culture, using a glucose oxidase method (glucose analyzer, Beckman Coulter, Inc., Fullerton, CA). The glucose consumption rate by explants was calculated as the difference between the amount of glucose in fresh medium and that remaining after 24 h of culture and was expressed as micromoles per g tissue/24 h. DNA was measured in some fresh adipose tissue samples (50 -100 mg) using a spectrofluorometric method (21) .
Presentation of the results
Results are the mean Ϯ se for the indicated numbers of patients (i.e. numbers of independent cultures). As data were not normally distributed, they were first normalized by log transformation before statistical analysis (22) . Comparisons between different conditions within a same group of patients were made using two-tailed paired Student's t test or repeated measures of ANOVA followed by the Dunnett's test (multiple comparisons vs. control) when appropriate. Comparisons between two different groups of subjects (e.g. lean vs. obese) were carried out using unpaired Student's t test. Differences were considered statistically significant at P Ͻ 0.05.
Results
Before the culture, the mRNA transcripts of PAI-1 (3.2 and 2.2 kb) were low in human omental adipose tissue (Fig. 1, A and D), in agreement with results obtained from sc fat (4, 11) . However, the transcripts were detectable after longer exposure of the blots [24 -48 h (not shown) vs. 4 -5 h (Fig. 1D) ]. These initial rather low levels of expression were not due to a reduction of the message during transport to the laboratory, as similar results were obtained in tissue freeze-clamped immediately after excision (not shown). As described in sc adipocytes and endothelial cells (4, 23) , PAI-1 mRNA and secretion increased spontaneously in omental fat during the first 12 h of culture in MEM (Fig. 1, A and B) . This rise occurred whether FCS was present (Fig. 1) or not (data not shown), ruling out the stimulatory effect of a serum-borne factor. After 12 h of culture, PAI-1 mRNA levels plateaued (4.7 Ϯ 1.2 and 4.4 Ϯ 0.8 OD at 12 and 24 h, respectively; n ϭ 5) while peptide production was still increasing (Fig. 1B) .
Dexamethasone added to the medium for up to 12 h (or 24 h; Fig. 1, inset) further enhanced PAI-1 secretion by adipose tissue in a time-dependent manner (P Ͻ 0.05 vs. respective values without dexamethasone from 8 h onward; Fig. 1B) . The stimulation by the glucocorticoid was preceded by a 2-fold rise (P Ͻ 0.05) in PAI-1 mRNA levels between 4 -8 h of culture, an effect that was specific, as GAPDH and PPAR␥ mRNAs were unaffected by the hormone (Fig. 1 , A, C, and D).
The concentration dependence of the effects of dexameth- asone on PAI-1 gene expression and protein production was examined after 6 h (24 h; Fig. 2, inset) of culture. The glucocorticoid was effective at concentrations above 1-10 nmol/L. The maximal effect was obtained at 100 -1000 nmol/L, and it may roughly be estimated that 50% of this effect occurred at approximately 10 -30 nmol/L (Fig. 2) .
The stimulation of PAI-1 production by dexamethasone was next compared in omental and sc adipose tissue sites after 24 h of culture (Fig. 3) . The basal, spontaneous secretion rate of PAI-1 by omental fat exceeded that by sc fat. The stimulation by dexamethasone occurred in both adipose sites, although the stimulated secretion rate remained higher in omental fat. The net absolute effect produced by 24-h dexamethasone (after subtraction of basal levels) tended also to be larger (P ϭ 0.057) in omental (maximal change in PAI-1, 2.2 Ϯ 0.5 g/g⅐24 h) than in sc (1.1 Ϯ 0.3 g/g⅐24 h) fat (Fig. 3) .
When lean and obese subjects were compared for 24-h basal or dexamethasone-stimulated PAI-1 production by omental fat, there were no differences between the two groups when data were expressed as micrograms per g tissue ( Table 1) . Because of the lower concentration of DNA in obese fat [195 Ϯ 22 ng/g tissue (obese; n ϭ 7) vs. 292 Ϯ 35 (lean; n ϭ 6); P Ͻ 0.05], which is probably due to fewer, but larger, fat cells per g tissue (11) , when PAI-1 data were expressed as micrograms per g tissue DNA, secretion rates tended to be higher (40 -60%) in the obese (Table 1) . However, this difference did not reach statistical significance, possibly because of the small number of subjects studied.
Unlike dexamethasone, 100 nmol/L insulin, either alone or combined with the glucocorticoid for 24 h, did not affect PAI-1 secretion by human omental fat. PAI-1 mRNA abundance was also unaffected (Fig. 4) . However, insulin exerted its stimulatory effect on glucose metabolism and accelerated glucose consumption rates by explants by about 40 -45%. Qualitatively similar results were obtained for PAI-1 mRNA (n ϭ 3; not shown) and secretion (Fig. 4, inset) in sc adipose tissue.
In contrast to insulin, dibutyryl cAMP [(Bu) 2 cAMP] for 24 h decreased PAI-1 mRNA and secretion by about 80% in omental fat and prevented the stimulatory effect of dexamethasone by about 50% (Fig. 5) .
The time course of the effects of cAMP on PAI-1 gene expression and protein production is illustrated in Fig. 6 . After an overnight culture (ϳ18 h) in MEM, PAI-1 mRNA levels were elevated. When adipose tissue was cultured for another 12 h in control MEM, these high levels remained fairly stable. In contrast, the addition of 1 mmol/L (Bu) 2 cAMP decreased PAI-1 mRNA abundance, an effect already detectable after 1 h and maximal (90%) after 4 h. PAI-1 secretion was also attenuated by cAMP; this inhibition was delayed by about 4 -8 h compared with that of mRNA levels and amounted to about 50% at 12 h. This inhibitory effect was also observed with another cAMP analog, with isobutylmethylxanthine (IBMX) or adrenoceptor agonists (Fig. 7) . Thus, bromo-cAMP (Br-cAMP) added to the medium for 12 h markedly decreased PAI-1 mRNA levels [65% inhibition vs. 90% for (Bu) 2 cAMP; no significant difference]. IBMX (a phosphodiesterase inhibitor that indirectly elevates intracellular cAMP levels) produced a 50% fall in PAI-1 mRNA abundance. Importantly, epinephrine, an ␣ 2 -and ␤-adrenergic agonist, dose dependently inhibited the accumulation of PAI-1 mRNA after 8 h of culture. This effect was reproduced by isoproterenol, a pure ␤-adrenergic agonist. The latter was also shown to inhibit PAI-1 secretion. Propanolol (100 mol/L), a ␤-adrenergic receptor antagonist, prevented the isoproterenol-induced inhibition of PAI-1 mRNA (73 Ϯ 20% of control levels for isoproterenol plus propanolol vs. 31 Ϯ 9% for isoproterenol alone; n ϭ 4; P Ͻ 0.05). The negative effect of (Bu) 2 cAMP was also observed in sc fat (Fig. 7, inset) .
Lastly, because PAI-1 may be produced by human stromal-vascular cells from adipose tissue (4, 24), we compared the hormonal regulation of PAI-1 gene expression by loading equal amounts of total RNA prepared from entire omental adipose tissue (explants), isolated adipocytes, and stromalvascular cells (Fig. 8) . In agreement with a previous study (4), basal PAI-1 mRNA levels in isolated adipocytes were close to those in explants at 0 and 4 h, whereas PAI-1 mRNA in stromal-vascular cells tended to be higher. Importantly, the regulation of PAI-1 mRNA was similar in both isolated adipocytes and explants: stimulation by dexamethasone and inhibition by cAMP. In isolated stromal-vascular cells, dexamethasone also produced a similar relative rise in PAI-1 mRNA (ϳ1.6-fold above basal levels), but cAMP was without significant effect. The contrast between the pronounced inhibition by cAMP in explants and the minimal effect in stromal-vascular cells, if any, suggests that alterations in PAI-1 gene expression in total adipose tissue is mainly explained by alterations in PAI-1 in adipocytes rather than in stromal-vascular cells.
Discussion
Dexamethasone stimulates PAI-1 gene expression and secretion in cultured human fat. This effect is observed at physiological concentrations of the hormone in lean and obese subjects and occurs in adipocytes and stromal-vascular cells and in both adipose tissue sites studied. Unlike dexamethasone, insulin per se does not affect PAI-1 secretion. In contrast, cAMP and catecholamines markedly decrease PAI-1 production in human fat; this inhibition is mainly mediated by pretranslational mechanisms and specifically exerted on adipocytes.
We confirm that basal production of PAI-1 (micrograms per g tissue) is higher in omental than in sc explants of adipose tissue (4) . We further demonstrate that this regional difference persists under stimulated (i.e. dexamethasone) conditions. This difference could partly be explained by depot variations in fat cell size and number. Omental fat cells are slightly smaller but greater in number than sc fat cells (25) . Thus, the regional difference in PAI-1 production could be slightly attenuated if secretion was expressed per fat cell. Regional variations in the cellular composition of the stromal-vascular fraction could also potentially contribute to this regional difference in secretion. Whatever the exact mechanism, omental adipose tissue produces more PAI-1 per g than the sc adipose depot. A reverse regional pattern of secretion has been previously observed for leptin, another adipocyte-derived secretory product (25) . Taken together, these data extend the concept that adipose tissue is not only a heterogeneous metabolic, but also a secretory, organ.
We next compared basal and stimulated PAI-1 secretion rates by omental adipose explants between lean and obese subjects. We found no differences between the two groups when data were expressed per g tissue. This contradicts a previous report on adipose explants from obese individuals, which were incubated for 2 h and exhibited increased basal PAI-1 production per g tissue (11) . This difference may be due to the fact that Eriksson (11) examined adipose tissue from the sc tissue, not from the omental region. Another possibility may be the persisting influence of in vivo circulating factors. After 2 h of culture in basal medium (11) , adipose tissue may still be under the influence of circulating stimulatory factors, and an enhanced secretion rate may still ensue, whereas after 24 h of culture, as in our study, this influence may have vanished. Yet, PAI-1 secretion rates tended to be higher in obese than in lean subjects when our data were expressed per g DNA. This may be explained by the fact that there are fewer fat cells per g tissue in the obese. This suggests that PAI-1 production per fat cell may actually were added, after an overnight preculture, to a fresh medium for 12 h. Inset, Effect of (Bu) 2 cAMP on sc adipose tissue from another series of subjects. When epinephrine (E; 10 Ϫ5 -10 Ϫ4 mol/L) and isoproterenol (Iso; 10 Ϫ5 mol/L) were tested, they were added at the beginning of the culture for 8 h. mRNA levels were expressed as percentages of results from respective control explants. PAI-1 released in medium after 8 h of isoproterenol was expressed as micrograms per g tissue. Values are the mean Ϯ SE for three [(Bu) 2 cAMP], three (Br-cAMP), three (IBMX), six (E), and nine (Iso) subjects. Note that in this figure, omental and sc fat were not obtained from the same three patients. *, P Ͻ 0.05 or less for the effect of the test agent vs. respective controls.
be increased in the obese, a finding possibly due to the larger size of their adipocytes. This is consonant with the positive correlation previously described between adipose tissue secretion of PAI-1 and fat cell volume (11) . Thus, the greater contribution of adipose tissue to plasma PAI-1 levels in obesity may be explained by enlarged fat cell volume and increased total fat mass, combined with potential circulating stimulatory factors.
Glucocorticoids may be one of these factors. Dexamethasone stimulates PAI-1 secretion in a dose-and time-dependent manner. This stimulation was preceded by a rise in PAI-1 mRNA and thus involved, at least during earlier time points, pretranslational events. These could be mediated through the binding of the steroid-receptor complex to the glucocorticoid response element that has been identified in the regulatory region of the human PAI-1 gene (26, 27) . At later time points (i.e. at 24 h when PAI-1 mRNA no longer increased while PAI-1 protein was still produced), posttranslational mechanisms were also likely to contribute. The stimulation by dexamethasone was observed in both adipocytes and stromal-vascular cells. This finding is consonant with the positive effect of glucocorticoids previously reported in some, but not all (3 of 12), human cell lines, including ones derived from fibroblasts (28) . However, the relative contribution of total RNA extracted from stromal-vascular cells and adipocytes to total RNA from adipose explants is currently unknown. In a single report (29) , the contribution of the stromal-vascular fraction has been estimated to be 30% of the total RNA from whole human adipose tissue. This value may actually be overestimated in our explants, as all visible vessels and conjunctive tissue were carefully removed from adipose pieces. The marked inhibition of PAI-1 mRNA produced by cAMP in explants despite the lack of an obvious effect in stromal-vascular cells may also support the contention that total RNA from explants contained only a small amount of total RNA from the stromal-vascular fraction. Importantly, the half-maximal concentration for dexamethasone stimulation was about 10 -30 nmol/L in explants. These concentrations may be considered to be within the physiological range (from basal levels measured in the morning up to those reached after stressful stimuli) if dexamethasone concentrations are converted into cortisol concentrations on the basis of their respective glucocorticoid potencies of 30:1. The stimulation by dexamethasone was observed in both omental and sc adipose tissues; the effect in the latter is in agreement with a previous report (16) . However, the net increment (in absolute values) of PAI-1 induced by dexamethasone was higher in omental fat, probably because of the greater number of glucocorticoid receptors in this adipose region (30) . As omental, but not sc, adipose tissue may generate active cortisol (31), constant exposure and increased responsiveness of omental fat to glucocorticoids may contribute to enhanced PAI-1 production in central obesity and, therefore, lead to a greater incidence of cardiovascular disease.
Unlike dexamethasone, insulin, either alone or in combination with the glucocorticoid, had no significant stimulatory effect on PAI-1 secretion by human omental and sc fat. However, insulin has recently been reported to increase PAI-1 production by human sc adipose explants (16) . Yet, this increase was moderate (50%; compare with the 2-fold rise that we observed in the presence of dexamethasone) and was not reproduced by isolated human adipocytes. Together, these data may suggest that insulin has no or only a moderate effect on PAI-1 production by human adipose tissue. This is consonant with the lack of effect of euglycemic-hyperinsulinemic clamps on circulating PAI-1 activity in humans (5, 6, 32) . However, this contrasts with the marked increase in PAI-1 activity in plasma and PAI-1 mRNA in adipose tissue from mice acutely injected with insulin (15) . Insulin also potently increased PAI-1 synthesis by murine 3T3-L1 or -F442 adipocytes (15, 16) . Taken together, these data may emphasize species differences in PAI-1 regulation.
cAMP and catecholamines inhibit PAI-1 mRNA and production in human fat. This finding is in agreement with the negative effect of forskolin on PAI-1 secretion in adipose tissue explants (16) . The inhibition by cAMP was observed specifically in adipocytes and not in stromal-vascular cells. The latter observation may contrast with previous reports on human endothelial and fibrosarcoma cells (33, 34) . However, the cellular composition of the stromal-vascular fraction is heterogeneous, and the ratio of stromal cells to vascular endothelial cells in the pelleted fraction from human abdominal adipose tissue has been only poorly studied. Yet, this fraction has been characterized by immunocytochemistry in breast adipose tissue and found to be composed of approximately 85% stromal (containing preadipocytes), 6% endothelia, about 10% macrophages, and 1% duct epithelia (35) . The inhibition of PAI-1 by catecholamines in adipose tissue is novel and may be physiologically relevant. This effect of catecholamines is probably mediated through activation of ␤-adrenergic receptors. Indeed, isoproterenol inhibits PAI-1 mRNA more potently than epinephrine on a molar basis, and this effect is prevented by propanolol. This inhibition by catecholamines might be difficult to reconcile with elevated plasma PAI-1 activity in central obesity, as catecholamine action is increased in vitro in the omental depot (36, 37) . However, in vivo studies consistently reported blunted lipolytic responses to epinephrine infusion in obese subjects (38 -41) , more particularly those with central fat distribution (39) . The overall lipolytic rate in vivo reflects mainly the effect of catecholamines on the sc fat depot, which, due to its high proportion of the total fat mass, dominates the response quantitatively. These observations are consonant with the impaired lipolytic action of catecholamines on sc fat cells isolated from subjects with central obesity, a defect partly due to a reduction in sensitivity and/or number of ␤ 2 -adrenoceptors (14, 42, 43) . As far as adipose tissue responses to catecholamines (estimated by the lipolytic rates) can be extrapolated to PAI-1 production, one would expect an overall impaired action of these hormones (i.e. diminished inhibition) on fat from subjects with central obesity. This would contribute to the associated increase in plasma PAI-1 levels.
Besides hormones, cytokines, in particular tumor necrosis factor-␣ (TNF␣), may be involved in PAI-1 regulation. mRNA levels and secretion of TNF␣ are enhanced in adipocytes from obese rodents and humans (44, 45) . The cytokine is a potent inducer of PAI-1 gene expression in mouse fat tissue in vivo as well as in 3T3-L1 cells (8, 46) . However, the effects of TNF␣ on PAI-1 production by human adipose explants are still controversial (4, 47) .
In conclusion, we provide evidence for a reciprocal regulation of PAI-1 by dexamethasone (positive effector) and cAMP/catecholamines (negative effectors) in cultured human adipose tissue. This regulation operates mainly at the pretranslational level. The stimulation by glucocorticoids (and possibly the impaired inhibition by catecholamines) could contribute to the enhanced production of PAI-1 levels associated with central obesity and thereby be a link between this disorder and cardiovascular disease.
